ICI-198615
A detailed overview of the compound ICI-198615, its properties, and applications in medical research.
| Drug Information | |||
|---|---|---|---|
| Image | |||
| Identifiers
CAS Number ATC Code PubChem DrugBank ChemSpider ID UNII KEGG ChEBI ChEMBL IUPAC Name |
Chemical Data
C H N O Molecular Weight | ||
ICI-198615 is a synthetic compound that has been studied for its potential applications in medical research, particularly in the field of cardiovascular pharmacology. It is known for its role as a selective antagonist of the endothelin receptor, which is involved in the regulation of vascular tone and blood pressure.
Chemical Properties[edit | edit source]
ICI-198615 is a small molecule with a specific chemical structure that allows it to interact with endothelin receptors. The compound's molecular formula is CxHyNzOw, and it has a molecular weight of approximately XYZ g/mol. The structure of ICI-198615 includes several functional groups that contribute to its binding affinity and selectivity for the endothelin receptor.
Pharmacological Action[edit | edit source]
ICI-198615 functions primarily as an antagonist of the endothelin A receptor (ETA receptor). By blocking the action of endothelin-1, a potent vasoconstrictor, ICI-198615 can reduce vascular resistance and lower blood pressure. This makes it a compound of interest in the study of hypertension and other cardiovascular disorders.
Research and Development[edit | edit source]
The development of ICI-198615 was part of a broader effort to understand the role of endothelin in cardiovascular diseases. Studies have shown that endothelin-1 is involved in the pathophysiology of several conditions, including pulmonary arterial hypertension and heart failure. ICI-198615 has been used in preclinical studies to explore the therapeutic potential of endothelin receptor antagonists.
Clinical Implications[edit | edit source]
While ICI-198615 itself may not be used directly in clinical settings, its study has contributed to the development of other endothelin receptor antagonists that are used in the treatment of cardiovascular diseases. Understanding the mechanism of action of ICI-198615 has provided insights into the design of more effective and selective drugs.
Safety and Toxicology[edit | edit source]
As with any pharmacological agent, the safety profile of ICI-198615 is an important consideration. Preclinical studies have evaluated its potential toxic effects, and these findings are crucial for assessing the risk-benefit ratio of similar compounds in clinical use.
Also see[edit | edit source]
- Endothelin receptor
- Endothelin receptor antagonist
- Hypertension
- Pulmonary arterial hypertension
- Cardiovascular pharmacology
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
